Pacira Pharmaceuticals Sees Unusually Large Options Volume (PCRX)

Pacira Pharmaceuticals Inc (NASDAQ:PCRX) saw unusually large options trading on Monday. Stock traders bought 4,456 call options on the company. This represents an increase of 1,155% compared to the average volume of 355 call options.

In related news, CAO Kristen Marie Williams sold 10,000 shares of Pacira Pharmaceuticals stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $40.00, for a total value of $400,000.00. Following the completion of the sale, the chief accounting officer now owns 23,455 shares of the company’s stock, valued at approximately $938,200. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO David M. Stack sold 28,885 shares of Pacira Pharmaceuticals stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $40.19, for a total value of $1,160,888.15. The disclosure for this sale can be found here. Insiders have sold a total of 98,960 shares of company stock worth $3,868,341 over the last quarter. Company insiders own 6.60% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. Legacy Capital Partners Inc. boosted its position in shares of Pacira Pharmaceuticals by 6.5% during the 4th quarter. Legacy Capital Partners Inc. now owns 50,493 shares of the company’s stock valued at $2,305,000 after acquiring an additional 3,100 shares during the last quarter. Swiss National Bank boosted its position in shares of Pacira Pharmaceuticals by 4.0% during the 4th quarter. Swiss National Bank now owns 69,800 shares of the company’s stock valued at $3,186,000 after acquiring an additional 2,700 shares during the last quarter. California Public Employees Retirement System boosted its position in shares of Pacira Pharmaceuticals by 3.3% during the 4th quarter. California Public Employees Retirement System now owns 68,100 shares of the company’s stock valued at $3,109,000 after acquiring an additional 2,200 shares during the last quarter. Teacher Retirement System of Texas bought a new stake in shares of Pacira Pharmaceuticals during the 4th quarter valued at about $637,000. Finally, Tygh Capital Management Inc. bought a new stake in shares of Pacira Pharmaceuticals during the 4th quarter valued at about $4,161,000.

Pacira Pharmaceuticals (NASDAQ PCRX) opened at $38.00 on Thursday. The company has a current ratio of 6.99, a quick ratio of 6.24 and a debt-to-equity ratio of 1.03. The firm has a market capitalization of $1,540.00, a PE ratio of -29.01 and a beta of 1.88. Pacira Pharmaceuticals has a twelve month low of $29.81 and a twelve month high of $58.95.

Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its earnings results on Wednesday, November 8th. The company reported $0.11 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.04) by $0.15. The business had revenue of $67.30 million during the quarter, compared to analyst estimates of $68.99 million. Pacira Pharmaceuticals had a negative return on equity of 13.77% and a negative net margin of 18.25%. The company’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.20 EPS. equities research analysts expect that Pacira Pharmaceuticals will post -0.86 earnings per share for the current fiscal year.

Several brokerages recently weighed in on PCRX. Canaccord Genuity decreased their price objective on Pacira Pharmaceuticals from $46.00 to $42.00 and set a “hold” rating for the company in a report on Tuesday, January 30th. Oppenheimer reissued a “hold” rating on shares of Pacira Pharmaceuticals in a report on Thursday, November 9th. HC Wainwright reissued a “buy” rating and issued a $52.00 price objective on shares of Pacira Pharmaceuticals in a report on Thursday, November 9th. Royal Bank of Canada reissued a “buy” rating and issued a $54.00 price objective on shares of Pacira Pharmaceuticals in a report on Friday, October 13th. Finally, JPMorgan Chase & Co. began coverage on Pacira Pharmaceuticals in a report on Monday, December 18th. They issued a “neutral” rating and a $47.00 price objective for the company. Three equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company’s stock. Pacira Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $48.82.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at https://www.americanbankingnews.com/2018/02/08/pacira-pharmaceuticals-sees-unusually-large-options-volume-pcrx.html.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply